TABLE 3.
The prognostic data of LYVE‐1 in the included studies
| Study | Cancer type | N | OS | Other survival endpoints | Prognostic effect | ||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||||
| (12) | BC | 180 | ‐ | 0.013 | ‐ | .0088 (DDFS) | Unfavorable |
| (14) | BC | 67 | ‐ | 0.045 | ‐ | .29 (RFS) | Unfavorable |
| (16) | BC | 173/184 | 0.8 (0.5‐1.3) | 0.51 | 1.1 (0.8‐1.4) | .41 (RFS) | No effect |
| (15) | BC | 544 | 1.22 (1‐1.5) | 0.04 | ‐ | ‐ | Unfavorable |
| (20) | NSCLC | 82 | RR = 2.04 (0.993‐4.19) | 0.00 | ‐ | ‐ | Unfavorable |
| (17) | NSCLC | 40 | ‐ | 0.96 | ‐ | ‐ | No effect |
| (19) | LC | 58 | 0.80 (0.68‐0.94) | 0.006 | ‐ | ‐ | Favorable |
| (18) | NSCLC | 140 | 1.27 (0.42‐3.83) | 0.66 | ‐ | ‐ | No effect |
| (21) | Melanoma | 37 | 1.55 | 0.0028 | ‐ | <.0001 (DFS) | Unfavorable |
| (22) | CBM | 20 | ‐ | ‐ | 8.91 | .008 (MSS) | Unfavorable |
| (23) | CM | 109 | ‐ | ‐ | ‐ | <.001 (RFS; LSFS; DMFS; MSS) | Unfavorable |
| (24) | CM | 60 | ‐ | ‐ | ‐ | <.05 (RFS; LSFS; DMFS; MSS) | Unfavorable |
| (27) | HNSCC | 97 | ‐ | ‐ | ‐ | .0009 (DSS) | Unfavorable |
| (26) | OTSCC | 50 | 1.52 (0.55‐4.21) | 0.41 | ‐ | ‐ | No effect |
| (25) | OSCC | 128 | ‐ | ‐ | OR = 1.29 (1.19‐1.40) | <.001 (DSS) | Unfavorable |
| (28) | HCC | 173 | 3.067 (1.507‐6.273); | 0.002 | 1.394 (0.864‐2.203) | .16 (DFS) | Favorable |
| (29) | OC | 108 | 1.02 (1.00‐1.04) | 0.41 | 1.02 (1.00‐1.05) | .5 (PFS) | No effect |
| (30) | EC | 102 | 0.3 (0.1‐0.8) | 0.019 | 0.2 (0.1‐0.6) | .003 (PFS) | Unfavorable |
Abbreviations: BC, breast cancer; CBM, ciliary body melanomas; CI, confidence interval; CM, conjunctival melanoma; DDFS, distant disease–free survival; DFS, disease‐free survival; DMFS, distant metastasis–free survival; DSS, disease‐specific survival; EC, endometrial carcinoma; HCC, human hepatocellular carcinoma; HNSCC, head and neck squamous cell carcinoma; HR, hazard ratio; LC, lung cancer; LSFS, lymphatic spread free survival; LYVE‐1, lymphatic vessel endothelial hyaluronan receptor 1; MSS, melanoma‐specific survival; NSCLC, non–small cell lung cancer; OC, ovarian carcinoma; OR, odds ratio; OS, overall survival; OSCC, oral squamous cell carcinoma; OTSCC, oral tongue squamous cell carcinoma; PFS, progression free survival; RFS, relapse free survival.